MCID: ANP009
MIFTS: 41

Anaplastic Oligodendroglioma malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Oligodendroglioma

Aliases & Descriptions for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 50 56 52 69

Characteristics:

Orphanet epidemiological data:

56
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA251630
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 70 C0334590

Summaries for Anaplastic Oligodendroglioma

MalaCards based summary : Anaplastic Oligodendroglioma is related to oligodendroglioma and oligoastrocytoma, and has symptoms including headache and seizures. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are DNA Damage and Peroxisome. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased viability and neoplasm

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Related Disease Score Top Affiliating Genes
1 oligodendroglioma 10.8
2 oligoastrocytoma 10.2
3 optic disk drusen 10.2 IDH1 IDH2
4 enterovesical fistula 10.2 IDH1 IDH2
5 acrocallosal syndrome 10.2 IDH1 IDH2
6 neurilemmoma 10.2 IDH1 IDH2
7 testis refractory cancer 10.2 IDH1 IDH2
8 cystinosis, nephropathic 10.2 IDH1 IDH2
9 small cell osteogenic sarcoma 10.2 IDH1 IDH2
10 glycogen storage disease type 0 10.2 IDH1 IDH2
11 neuropathy, ataxia, and retinitis pigmentosa 10.2 IDH1 IDH2
12 breast papillomatosis 10.2 IDH1 IDH2
13 spinal cord astrocytoma 10.2 IDH1 IDH2
14 prosopagnosia 10.2 IDH1 IDH2
15 cystic lymphangioma 10.2 IDH1 IDH2
16 agammaglobulinemia 8, autosomal dominant 10.2 IDH1 IDH2
17 gummatous syphilis 10.2 IDH1 IDH2
18 apocrine sweat gland neoplasm 10.2 CDKN2A IDH1
19 t-cell adult acute lymphocytic leukemia 10.1 IDH1 IDH2
20 allergic hypersensitivity disease 10.1 IDH1 IDH2
21 vascular cancer 10.1 IDH1 IDH2
22 asynchronous multifocal osteogenic sarcoma 10.1 IDH1 IDH2
23 macrosomia with microphthalmia, lethal 10.1 IDH1 IDH2
24 penile disease 10.1 CDKN2A MSH6
25 basophilic carcinoma 10.1 IDH1 IDH2
26 astrocytoma 10.1
27 systemic lupus erythematosus 2 10.1 IDH1 IDH2
28 ophn1 syndrome 10.0 IDH2 MGMT
29 leukemia 10.0
30 glucosephosphate isomerase deficiency 10.0 CDKN2A IDH1 IDH2
31 cutaneous adenocystic carcinoma 10.0 IDH1 MGMT
32 trypanosomiasis 10.0 MGMT MSH6
33 endometrial squamous cell carcinoma 10.0 CDKN2A MGMT
34 primary tubular proximal acidosis 10.0 CDKN2A MGMT
35 arteriovenous malformation 10.0
36 glioblastoma 10.0
37 pancreatic invasive mucinous cystadenocarcinoma 9.9 CDKN2A MGMT
38 amyloid tumor 9.9 IDH1 IDH2 MGMT
39 rhabdomyosarcoma 9.9 CDKN2A MGMT
40 cerebritis 9.9
41 anaplastic oligoastrocytoma 9.9
42 brain cancer 9.9
43 early myoclonic encephalopathy 9.9 IDH1 MGMT
44 glomeruloid hemangioma 9.9 CDKN2A IDH1 MGMT
45 malignant pleural solitary fibrous tumor 9.8 CDKN2A IDH1 MGMT
46 interstitial lung disease 9.8 CDKN2A IDH2 MGMT
47 adult astrocytic tumour 9.8 CDKN2A IDH1 MGMT
48 grade iii astrocytoma 9.8 CDKN2A IDH1 MGMT
49 marginal zone b-cell lymphoma 9.8 CDKN2A MGMT
50 hidradenoma 9.8 CDKN2A MGMT MSH6

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


headache, seizures

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.28 CDKN2A CDKN2C POT1
2 Decreased viability GR00221-A-3 9.28 CDKN2A POT1
3 Decreased viability GR00221-A-4 9.28 CDKN2A POT1
4 Decreased viability GR00301-A 9.28 CDKN2C
5 Decreased viability GR00342-S-2 9.28 CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.35 CDKN2A CDKN2C IDH2 MGMT MSH6
2 respiratory system MP:0005388 8.92 CDKN2A CDKN2C IDH1 MGMT

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved Phase 3,Phase 1,Phase 2 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
6
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
7
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
10
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
13
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
15 Analgesics Phase 3,Phase 2,Phase 1
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Dermatologic Agents Phase 3,Phase 1,Phase 2
18 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
19 Keratolytic Agents Phase 3,Phase 1,Phase 2
20 Antimitotic Agents Phase 3,Phase 1,Phase 2
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
23 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
24 pancreatic polypeptide Phase 3,Phase 1
25 Cholinergic Agents Phase 3,Phase 2
26 Adjuvants, Anesthesia Phase 3
27 Cholinesterase Inhibitors Phase 3,Phase 2
28 Narcotics Phase 3
29 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
30 Neurotransmitter Agents Phase 3,Phase 2
31 Nootropic Agents Phase 3,Phase 2
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3,Phase 1
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Liver Extracts Phase 3,Phase 2,Phase 1
37 Central Nervous System Stimulants Phase 3,Phase 2
38 Dopamine Agents Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40
Serotonin Phase 3 50-67-9 5202
41 Serotonin Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44 Histamine Antagonists Phase 3
45 Histamine H1 Antagonists Phase 3
46 Dexmethylphenidate Hydrochloride Phase 3
47 Dopamine Uptake Inhibitors Phase 3
48 Anti-Allergic Agents Phase 3
49 Antipruritics Phase 3
50 Cola Nutraceutical Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 267)
id Name Status NCT ID Phase
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3
3 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
7 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3
8 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
10 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
11 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
12 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
13 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Unknown status NCT00003472 Phase 2
14 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2
15 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
16 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
17 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2
18 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Unknown status NCT01026493 Phase 1, Phase 2
19 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
20 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2
21 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2
22 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2
23 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2
24 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2
25 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2
26 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2
27 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2
28 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2
29 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2
30 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2
31 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide Completed NCT00369590 Phase 2
32 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2
33 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2
34 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2
35 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2
36 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2
37 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2
38 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
39 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2
40 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2
41 Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Completed NCT00087061 Phase 1, Phase 2
42 EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Completed NCT00006093 Phase 1, Phase 2
43 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Completed NCT00404248 Phase 1, Phase 2
44 Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas Completed NCT00268359 Phase 2
45 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2
46 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2
47 Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00005855 Phase 1, Phase 2
48 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2
49 COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00004147 Phase 1, Phase 2
50 Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors Completed NCT00003574 Phase 2

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Anatomical Context for Anaplastic Oligodendroglioma

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

39
Brain, Bone, Bone Marrow, Spinal Cord, Endothelial, B Cells, Tongue

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 124)
id Title Authors Year
1
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
2
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
3
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
4
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
5
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
6
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
7
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
8
A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging. ( 26622514 )
2015
9
TCF12 is mutated in anaplastic oligodendroglioma. ( 26068201 )
2015
10
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. ( 26018682 )
2015
11
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( 26352098 )
2015
12
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. ( 26354927 )
2015
13
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. ( 26167373 )
2015
14
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( 25534576 )
2015
15
A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. ( 26341368 )
2015
16
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
17
Novel MSH6 mutations in treatment-naA^ve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( 25078279 )
2014
18
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
19
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. ( 24447608 )
2014
20
Cavernous angioma within the context of anaplastic oligodendroglioma: case report and review of the literature. ( 24844794 )
2014
21
Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. ( 23711170 )
2014
22
Increased 99mTc TRODAT-1 Uptake in Anaplastic Oligodendroglioma. ( 23603602 )
2014
23
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
24
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
25
Extraneural metastases of anaplastic oligodendroglioma. ( 24373094 )
2013
26
Erratum to: Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17A years of dormancy: an autopsy case report. ( 24036579 )
2013
27
Anaplastic oligodendroglioma in an adolescent with Lynch syndrome. ( 23255519 )
2013
28
Pitfalls of conservative treatments of multiple probable cerebral cavernous malformations (CCMs): clinicopathological features of CCMs coexisting with vasculogenic mimicry in an anaplastic oligodendroglioma. ( 24337536 )
2013
29
Differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma: a case report of an elderly man. ( 23979650 )
2013
30
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. ( 23071247 )
2013
31
Anaplastic oligodendroglioma: advances and treatment options. ( 23344797 )
2013
32
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( 23071237 )
2013
33
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. ( 25054579 )
2013
34
Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17A years of dormancy: an autopsy case report. ( 23900511 )
2013
35
Minding the Ps and Qs: perseverance and quality studies lead to major advances in patients with anaplastic oligodendroglioma. ( 23071223 )
2013
36
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
37
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. ( 23907441 )
2013
38
Feline anaplastic oligodendroglioma: long-term remission through radiation therapy and chemotherapy. ( 23651604 )
2013
39
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. ( 23681562 )
2013
40
Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. ( 24527191 )
2013
41
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
42
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. ( 23527265 )
2013
43
Breast metastasis of anaplastic oligodendroglioma: a case report. ( 23389376 )
2012
44
Unusual intracranial spread of anaplastic oligodendroglioma. ( 22891021 )
2012
45
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU. ( 22785244 )
2012
46
Brain cancer. Fine-tuning chemoradiotherapy for anaplastic oligodendroglioma. ( 23149899 )
2012
47
Anaplastic oligodendroglioma involving the subcutaneous tissue of the scalp: report of an exceptional case and review of the literature. ( 22157246 )
2012
48
Paraplegia due to drop metastases from anaplastic oligodendroglioma. ( 21591854 )
2012
49
Anaplastic oligodendroglioma with ganglioglioma-like maturation. ( 22231405 )
2012
50
Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. ( 23243547 )
2012

Variations for Anaplastic Oligodendroglioma

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.39 CDKN2A CDKN2C MGMT MSH6
2 11.24 IDH1 IDH2
3 11.12 CDKN2A MSH6
4 10.66 CDKN2A CDKN2C
5
Show member pathways
10.07 IDH1 IDH2

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tricarboxylic acid cycle GO:0006099 9.4 IDH1 IDH2
2 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.37 CDKN2A CDKN2C
3 negative regulation of phosphorylation GO:0042326 9.32 CDKN2A CDKN2C
4 2-oxoglutarate metabolic process GO:0006103 9.26 IDH1 IDH2
5 positive regulation of helicase activity GO:0051096 9.16 MSH6 POT1
6 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
7 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 magnesium ion binding GO:0000287 9.5 IDH1 IDH2 MSH6
2 NAD binding GO:0051287 9.4 IDH1 IDH2
3 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.37 IDH1 IDH2
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN2C
5 oxidized purine DNA binding GO:0032357 9.16 MSH6 POT1
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
7 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Anaplastic Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....